VER-01
NDA- Indications
- Chronic pain
Company intelligence / Profile preview
BiomicaLabs is a Munich-based biotechnology company and a subsidiary of the FUTRUE group, specializing in the development of artificial microbiomes for the treatment of serious diseases. The company's core technology, Mikro7, is a laboratory-engineered microbiome designed to restore health by fundamentally addressing microbiome-related pathologies. Founded by Dr. Clemens Fischer, BiomicaLabs aims to revolutionize the field of microbial therapy through the targeted transfer of these artificial consortia. The company is currently in the pre-clinical stage, with plans to initiate clinical trials in 2025.
6 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on BiomicaLabs.